Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

611 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
ESRD After Heart Failure, Myocardial Infarction, or Stroke in Type 2 Diabetic Patients With CKD.
Charytan DM, Solomon SD, Ivanovich P, Remuzzi G, Cooper ME, McGill JB, Parving HH, Parfrey P, Singh AK, Burdmann EA, Levey AS, de Zeeuw D, Eckardt KU, McMurray JJV, Claggett B, Lewis EF, Pfeffer MA. Charytan DM, et al. Among authors: levey as. Am J Kidney Dis. 2017 Oct;70(4):522-531. doi: 10.1053/j.ajkd.2017.04.018. Epub 2017 Jun 7. Am J Kidney Dis. 2017. PMID: 28599901
Baseline characteristics in the Trial to Reduce Cardiovascular Events With Aranesp Therapy (TREAT).
Pfeffer MA, Burdmann EA, Chen CY, Cooper ME, de Zeeuw D, Eckardt KU, Ivanovich P, Kewalramani R, Levey AS, Lewis EF, McGill J, McMurray JJ, Parfrey P, Parving HH, Remuzzi G, Singh AK, Solomon SD, Toto R, Uno H; TREAT Investigators. Pfeffer MA, et al. Among authors: levey as. Am J Kidney Dis. 2009 Jul;54(1):59-69. doi: 10.1053/j.ajkd.2009.04.008. Epub 2009 Jun 5. Am J Kidney Dis. 2009. PMID: 19501439 Clinical Trial.
Estimated GFR decline as a surrogate end point for kidney failure: a post hoc analysis from the Reduction of End Points in Non-Insulin-Dependent Diabetes With the Angiotensin II Antagonist Losartan (RENAAL) study and Irbesartan Diabetic Nephropathy Trial (IDNT).
Lambers Heerspink HJ, Weldegiorgis M, Inker LA, Gansevoort R, Parving HH, Dwyer JP, Mondal H, Coresh J, Greene T, Levey AS, de Zeeuw D. Lambers Heerspink HJ, et al. Among authors: levey as. Am J Kidney Dis. 2014 Feb;63(2):244-50. doi: 10.1053/j.ajkd.2013.09.016. Epub 2013 Nov 6. Am J Kidney Dis. 2014. PMID: 24210590 Clinical Trial.
Cause of Death in Patients With Diabetic CKD Enrolled in the Trial to Reduce Cardiovascular Events With Aranesp Therapy (TREAT).
Charytan DM, Lewis EF, Desai AS, Weinrauch LA, Ivanovich P, Toto RD, Claggett B, Liu J, Hartley LH, Finn P, Singh AK, Levey AS, Pfeffer MA, McMurray JJ, Solomon SD. Charytan DM, et al. Among authors: levey as. Am J Kidney Dis. 2015 Sep;66(3):429-40. doi: 10.1053/j.ajkd.2015.02.324. Epub 2015 Apr 29. Am J Kidney Dis. 2015. PMID: 25935581 Free PMC article. Clinical Trial.
C-Reactive Protein and Risk of ESRD: Results From the Trial to Reduce Cardiovascular Events With Aranesp Therapy (TREAT).
Mc Causland FR, Claggett B, Burdmann EA, Eckardt KU, Kewalramani R, Levey AS, McMurray JJ, Parfrey P, Remuzzi G, Singh AK, Solomon SD, Toto RD, Pfeffer MA. Mc Causland FR, et al. Among authors: levey as. Am J Kidney Dis. 2016 Dec;68(6):873-881. doi: 10.1053/j.ajkd.2016.07.022. Epub 2016 Sep 16. Am J Kidney Dis. 2016. PMID: 27646425 Free PMC article. Clinical Trial.
Change in Hemoglobin Trajectory and Darbepoetin Dose Approaching End-Stage Renal Disease: Data from the Trial to Reduce Cardiovascular Events with Aranesp Therapy Trial.
Mc Causland FR, Claggett B, Pfeffer MA, Burdmann EA, Eckardt KU, Levey AS, McMurray JJV, Remuzzi G, Singh AK, Solomon SD, Toto RD, Parfrey P. Mc Causland FR, et al. Among authors: levey as. Am J Nephrol. 2017;46(6):488-497. doi: 10.1159/000485326. Epub 2017 Dec 14. Am J Nephrol. 2017. PMID: 29241199 Free PMC article. Clinical Trial.
Treatment of Anemia With Darbepoetin Prior to Dialysis Initiation and Clinical Outcomes: Analyses From the Trial to Reduce Cardiovascular Events With Aranesp Therapy (TREAT).
Mc Causland FR, Claggett B, Burdmann EA, Chertow GM, Cooper ME, Eckardt KU, Ivanovich P, Levey AS, Lewis EF, McGill JB, McMurray JJV, Parfrey P, Parving HH, Remuzzi G, Singh AK, Solomon SD, Toto RD, Pfeffer MA. Mc Causland FR, et al. Among authors: levey as. Am J Kidney Dis. 2019 Mar;73(3):309-315. doi: 10.1053/j.ajkd.2018.10.006. Epub 2018 Dec 19. Am J Kidney Dis. 2019. PMID: 30578152 Free PMC article. Clinical Trial.
Metformin use and cardiovascular events in patients with type 2 diabetes and chronic kidney disease.
Charytan DM, Solomon SD, Ivanovich P, Remuzzi G, Cooper ME, McGill JB, Parving HH, Parfrey P, Singh AK, Burdmann EA, Levey AS, Eckardt KU, McMurray JJV, Weinrauch LA, Liu J, Claggett B, Lewis EF, Pfeffer MA. Charytan DM, et al. Among authors: levey as. Diabetes Obes Metab. 2019 May;21(5):1199-1208. doi: 10.1111/dom.13642. Epub 2019 Mar 4. Diabetes Obes Metab. 2019. PMID: 30672083 Clinical Trial.
611 results